-+ 0.00%
-+ 0.00%
-+ 0.00%

CAMP4 THERAPEUTICS RECEIVES CLINICAL TRIAL APPLICATION APPROVAL FOR PHASE 1/2 CLINICAL TRIAL OF CMP-002 IN PATIENTS WITH SYNGAP1-RELATED DISORDER IN THE EUROPEAN UNION

Reuters·10/27/2026 12:00:06

Please log in to view news